HER-2 neu expression in surface epithelial ovarian tumors and its relationship with clinic-pathological parameters: a pilot study

Authors

  • Abhimanyu Grover Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India
  • Madhusmita Mohanty Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India http://orcid.org/0000-0002-3083-6621
  • Kanakalata Dash Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20210960

Keywords:

Surface epithelial tumor, HER2/neu, Immunohistochemistry

Abstract

Background: Ovarian cancer is one of the major source of morbidity and mortality in women among all gynecological malignancies. Her2/neu expression in ovarian carcinoma has not been studied extensively in ovarian surface epithelial carcinoma. It's can be utilized towards future proposed studies as a targeted therapy in new era of treatment for ovarian malignancies.

Methods: It was a prospective study carried for 2 years. Hematoxylin and eosin stain was studied, grading, staging was evaluated for all the cases. Immunohistochemical staining with HER2/neu was done, evaluation done by 3 independent pathologists, correlation of HER2/neu with histological type, grade and stage was done.  

Results: The present study included 33 cases of histologically proven epithelial ovarian neoplasm with mean age of 44.5±25.55 years. Serous type constitutes majority of cases (48.48%), maximum number of cases was in high grade (57.57%) and high stage (40.74%). Majority of tumors showed negative expression of HER2/neu i.e. 42.42%. The current study found no significant correlation between HER2/neu expression and histological type, histological grade, extent of tumor (T stage) and distant metastasis. But we found a significant correlation between nodal metastasis and HER2/neu expression.

Conclusions: HER2/neu therapy can be given in borderline and low grade tumor compared to high grade tumor.

Author Biographies

Abhimanyu Grover, Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

Department of Pathology,Junior resident .

Madhusmita Mohanty, Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

Assistant Professor, Department of Pathology

Kanakalata Dash, Department of Pathology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

Professor, Department of Pathology

References

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. Cancer J Clin. 2018;68:284-96.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9-32.

Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.

Fukushige SI, Matsubara K, Yoshida MI, Sasaki MO, Suzuki TO, Semba K, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Molecul Cellul Biol. 1986;6(3):955-8.

Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathol. 2007;20(1):120-9.

Prat J. Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma. AJCC Cancer Staging Manual, Eight Edition. 2015;55:689-98.

Cirstea AE, Stepan AE, Margaritescu C, Zavoi RE, Olimid DA, Simionescu CE. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom J Morphol Embryol. 2017;58(4):1269-73.

Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Canc. 2004;14(6).

Goel S, Mehra M, Yadav A, Sharma M.A Comparative study of HER-2/neu Oncogene in benign and malignant ovarian tumors. Int J Scient Stud. 2014;2:21-7 .

Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, et al. The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget. 2016;7(9):10568.

Asadinejad E, Abdirad A, Nili F, Soleimani V. HER2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-sectional Study in an Iranian Population and Literature Review. Mid East J Canc. 2018;9(4):300-9.

Ndukwe CO, Asomugha LA, Ukah CO. Profile of human epidermal growth factor receptor 2 expression in epithelial ovarian carcinomas: A multicenter study from southeast Nigera. J Scientif Soc. 2018 ;5:57-62.

Cirstea AE, Stepan AE, Margaritescu C, Zavoi RE, Olimid DA, Simionescu CE. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom J Morphol Embryol. 2017;58(4):1269-73.

Downloads

Published

2021-03-24

Issue

Section

Original Research Articles